Marshall Wace
NGM

Marshall Wace’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Marshall Wace’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-86,027
Closed -$1.81M – 4397
2021
Q3 		$1.81M Buy
+86,027
New +$1.89M 0.01% 1631
2021
Q2 		– Sell
-45,577
Closed -$1.32M – 3226
2021
Q1 		$1.32M Buy
+45,577
New +$1.28M 0.01% 1519
2020
Q2 		– Sell
-228,551
Closed -$2.82M – 2038
2020
Q1 		$2.82M Buy
+228,551
New +$3.73M 0.03% 518

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCP
Rho Capital Partners New York $20.4M AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PIM
Ponoi II Management San Francisco, California $38.3M AUM 32.02% 1-Year Est. Return
PM
Ponoi Management San Francisco, California $73.2M AUM 23.44% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Marshall Wace's NGM Position: Q4 2021 in Review

Marshall Wace sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q4 2021, closing a stake of 86,027 shares — an estimated $1.81M sold.

Marshall Wace first reported a position in NGM in Q1 2020 and held it in 3 quarters. The position peaked at $2.82M in Q1 2020. 119 funds tracked by Wall St. Rank hold NGM as of Q4 2021.

  • Marshall Wace reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Marshall Wace sold 86,027 NGM Biopharmaceuticals, Inc. Common Stock shares in Q4 2021, an estimated $1.81M.
  • Marshall Wace first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 3 quarters.
  • Marshall Wace's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.82M in Q1 2020.
  • 119 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q4 2021.

Based on Marshall Wace's 13F filing for Q4 2021, filed 14 Feb 2022.